Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"RGS is actively seeking Japanese partners for its adipose-derived mesenchymal stem cell osteoarthritis drug, Progenza." (8/5/15) Regeneus Ltd. - The Life Sciences Report Interview with Colin Lee Novick More >
Companies Commented On
- Applied Genetic Technologies Corp.
- Argos Therapeutics Inc.
- BioLineRx Ltd.
- Can-Fite BioPharma Ltd.
- Celator Pharmaceuticals Inc.
- Concert Pharmaceuticals
- ContraFect Corp.
- CTI BioPharma
- Cytokinetics Inc.
- Cytori Therapeutics Inc.
- DelMar Pharmaceuticals Inc.
- Dendreon Corp.
- Galena Biopharma Inc.
- GenVec Inc.
- ImmunoCellular Therapeutics Ltd.
- Lion Biotechnologies
- MEI Pharma Inc.
- OncoSec Medical Inc.
- Oncothyreon Inc.
- Palatin Technologies Inc.
- Paratek Pharmaceuticals Inc.
- Peregrine Pharmaceuticals Inc.
- Rexahn Pharmaceuticals Inc.
- Spectrum Pharmaceuticals Inc.
- Stemline Therapeutics Inc.
- Sunesis Pharmaceuticals Inc.
- Synta Pharmaceuticals Corp.
- TG Therapeutics Inc.
- Threshold Pharmaceuticals Inc.
- Vascular Biogenics Ltd.
- Verastem Inc.
- Viralytics Ltd.
- ZZ-OLD Lion Biotechnologies Inc.
Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JBHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.
Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners (6/17/15) The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth.
A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15) It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.
Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >
"SNSS is targeting its formal meeting with the FDA in mid-2015 and, if successful, a rolling NDA submission in H2/15." (5/13/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Joe Pantginis More >
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"When I can get potential blue-sky regenerative technologies like RP's at this small valuation, I'm buying." (8/12/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Eden Rahim More >